IDF Premium courses

T2DM - Oral Agents Fact Checking

A customised set of modules addressing the ongoing needs of health professionals to manage type 2 diabetes using oral glucose-lowering agents.

uems

7 Crédits CME européens

4.6 (497)

Inscrits:

2978 Apprenants

Vues:

164763

IDF Premium courses

Sélectionner la langue

À propos de ce cours

This course will enhance core skills and competencies of health professionals to effectively manage type 2 diabetes using oral glucose-lowering agents.

A qui s'adresse ce cours ?

All health professionals involved in diabetes management and care are eligible to take the course. In particular, health professionals who work in isolated, remote settings and lack access to latest evidence-based education resources.

Programme d'études

Auto-évaluation initiale

Complétez votre auto-évaluation initiale avant de commencer les modules du cours.

Learning Objectives:

At the end of this module the learner will be able to:

  • Define the purpose and rationale for using oral glucose-lowering agents in type 2 diabetes mellitus (T2DM)
  • Describe the evidence for glucose-lowering therapy intensification to achieve tighter glycaemic control and improve long-term outcomes
  • Review classes of oral glucose-lowering agents and their comparative efficacy
  • Explain how to use newer and older oral glucose-lowering agents alone and in combination to achieve better glycaemic control
Learning Objectives:

At the end of this module the learner will be able to:

  • Compare effectiveness of oral glucose-lowering therapies to provide robust decreases in HbA1c
  • Compare and contrast inter- and intraclass risks of severe hypoglycaemia with oral glucose-lowering therapies
  • Describe potential benefits of oral glucose-lowering therapies to improve cardiovascular and renal outcomes and promote weight loss/neutrality
  • Discuss the cost-effectiveness of oral agents in the context of efficacy and safety in various settings
Learning Objectives:

At the end of this module the learner will be able to:

  • Discuss the risks and benefits of glucocentric and cardiocentric treatment approaches in type 2 diabetes mellitus (T2DM)
  • Review data that demonstrate the complementary nature of cardiocentric and glucocentric strategies to achieve optimal outcomes in T2DM
  • Adopt an individualised approach to T2DM management that balances potential benefits and harms in the context of patient preferences, goals and barriers to treatment
Learning Objectives:

At the end of this module the learner will be able to:

  • Apply current data and guidelines to various clinical scenarios
  • Identify patients who would benefit from, and then develop an individualised approach to, intensifying treatment
Learning Objectives:

At the end of this module the learner will be able to:

  • Explain the relationship between hyperglycaemia and hypertension on total cardiovascular disease risk
  • Describe potential benefits and risks of intensive blood pressure control in patients with T2DM
  • Contrast and discuss international guidelines for the management of hypertension and T2DM for appropriate hypertension and oral glycemic agent therapy selection
  • Adopt an individualised approach to hypertension management in T2DM that considers potential benefits and harms in the context of comorbidities
Learning Objectives:

At the end of this module the learner will be able to:

  • Describe considerations in a holistic person-centred management approach for patients with T2DM
  • Discuss effective physician–patient communication strategies related to principles of care, such as social determinants of health, shared decision-making, and psychosocial factors
  • Outline individualised treatment targets and treatment options with oral agents based on patient factors and circumstances
Learning Objectives:

At the end of this module the learner will be able to:

  • Explain the relationship between hyperglycaemia and dyslipidaemia on total cardiovascular disease risk.
  • Describe the importance of intensive lipid-lowering therapy in people with T2DM.
  • Contrast and discuss international guidelines for the management of dyslipidaemia and T2DM for appropriate dyslipidaemia and oral glucose-lowering agent therapy selection.
  • Adopt an individualised approach to dyslipidaemia management in people with T2DM in the context of comorbidities.

Complétez votre auto-évaluation finale pour continuer.

Veuillez partager vos commentaires avant de télécharger votre certificat.

Vous pouvez télécharger votre certificat ici.

coc courses

Comment ça marche ?

Certificat

An IDF Certificate with 7 European CME credits will be awarded upon completion of all seven modules.

Existing learners who completed the original six modules must finish the new module to receive the updated certificate.


For new learners: Modules 1-4, Modules 5-6, and Module 7 can be started independently, but the certificate is only available after completing all seven modules

Prix du cours

The online course is supported by an educational grant from

This course is free of charge.

The course content was created by the International Centre for Professional Development in Health and Medicine (ICPDHM), along with a group of multidisciplinary international experts and further digitised by IDF for wider dissemination and access.

COMMENTAIRES

4.6

Note moyenne

(497 votes)
  • 67%
  • 31%
  • 2%
  • 0%
  • 0%
Détails du cours
Modules:

7

Durée du cours:

8 hours

Approx. 4 weeks to complete

:

English

This online module is supported by an educational grant from

Caractéristiques du cours

Apprentissage flexible à son propre rythme

Études de cas

Téléchargement des modules du cours

Certificat

Crédits CME européens

© 2022 - IDF - All Right Reserved | Privacy Policy 

Facebook
Twitter
Linkedin